OncoMatch/Clinical Trials/NCT07169851
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Is NCT07169851 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including LY3537021 and Standard of Care Antiemetic Therapies for nausea.
Treatment: LY3537021 · Standard of Care Antiemetic Therapies · Background Chemotherapy — The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Marin Cancer Care · Greenbrae, California
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- BASS Cancer Center · Walnut Creek, California
- UCHealth Harmony · Fort Collins, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07169851 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify